Private Care Magazine, Issue 4 - The Royal Marsden

More documents

Recommendations

Info

GYNAECOLOGY UNITLeading the wayin cancer careWe speak to three of The Royal Marsden’s consultantsabout their groundbreaking research into thetreatment of gynaecological cancers
Gynaecology focusDr Susan Lalondrellein the CyberKnife suitewith Lead RadiographerHelen TaylorTaylor, Consultant ClinicalOncologist. “The gynaecologicalservice at The Royal Marsdenprovides multidisciplinarycare for patients with anintegrated team approach by thesurgeons, medical oncologistsand clinical oncologists.”Above, from left: Dr SusanaBanerjee, Consultant MedicalOncologist; Dr SusanLalondrelle, ConsultantClinical Oncologist; and DrAlexandra Taylor, ConsultantClinical Oncologists Europe’s largestcancer centre, TheRoyal Marsden offersa complete range of treatment,from surgery and chemotherapyto state-of-the-art radiotherapyusing leading-edge equipment.Our Gynaecology Unit isan excellent example of ourcommitment to providingpatients with access to worldleadingoncologists and thevery best cancer care.Internationally recognisedsurgeons work in partnershipwith the oncologists to providecomprehensive radiotherapyand chemotherapy services.A large research practice alsomeans that patients benefit fromthe latest in drug development,which results in better outcomes.As a result of this approachand the hospital’s internationalreputation, The Royal Marsdenattracts the highest calibre ofmedical and research talent,whose specialist knowledge ingynaecological cancer meansthat our patients receive thebest treatment and care.We are proud to introducethree consultants in theGynaecology Unit – Dr SusanaBanerjee, Dr Alexandra Taylorand Dr Susan Lalondrelle – whoare leading the way with newresearch, treatments and services.“Patients with gynaecologicalcancer often need a combinationof surgery, chemotherapy andradiotherapy to optimise theirtreatment,” says Dr Alexandra“THE AVASTINBREAKTHROUGHIS VERY EXCITINGAND MEANS MORETREATMENT OPTIONSFOR PATIENTS”DR SUSANA BANERJEE, CONSULTANTMEDICAL ONCOLOGISTDr Susana BanerjeeDr Banerjee is a ConsultantMedical Oncologist and MedicalOncology Lead for Clinical Trialsand Translational Research (forGynaecological Cancers) at TheRoyal Marsden. Her researchinterests are the personalisationof patient treatment and targetedtherapies in women’s cancers,and she is leading a researchteam offering a portfolio of PhaseI–III clinical trials for patientswith gynaecological cancers.One of the most promising areasof drug development is in thetreatment of ovarian cancerwith bevacizumab, or Avastin.The drug works by attackingblood vessels that feed cancersand allow them to spread.Clinical trials have shown thatby combining bevacizumab withchemotherapy and continuingit afterwards (maintenance), thetime before the cancer progressescan be increased, as can thesurvival rate for some patientsat high risk of relapse.“This breakthrough is veryexciting and means moretreatment options for patients,”says Dr Banerjee. “Avastin isnow available to patients withovarian cancer as first-linetreatment, and patients withrecurrent disease are offered thisdrug at The Royal Marsden.”Dr Susan LalondrelleDr Lalondrelle, ConsultantClinical Oncologist, specialisesin treating gynaecological andskin cancers using radiotherapy,brachytherapy (internal radiation)and chemotherapy, workingclosely with her colleagues inThe Royal Marsden Private Care 5
Page 2 and 3: WelcomeIn our fourth edition of Pri
Page 6 and 7: Gynaecology focusGynaecologicalcanc
Page 8 and 9: Sarcoma Q&AQ&ASOFT-TISSUESARCOMASDr
Page 10 and 11: Skin and plastics focusSpotlight on
Page 12: Only Royal Marsden Private Care off

Private Care Magazine, Issue 4 - The Royal Marsden

Create successful ePaper yourself

Delete template?

Save as template?